




TRR 241
IEC in IBD

FAU
Friedrich-Alexander-Universität
Erlangen-Nürnberg

CHARITÉ
UNIVERSITÄTSMEDIZIN BERLIN

**UK
SH**


**MEDIZINISCHE
UNIVERSITÄT**
INNSBRUCK

DRFZ 
BERLIN
Deutsches Rheuma-Forschungszentrum
Ein Institut der Leibniz-Gemeinschaft

MDC MAX DELBRÜCK CENTER
FOR MOLECULAR MEDICINE
IN THE HELMHOLTZ ASSOCIATION

VISION 2030 CHANGING PARADIGMS IN INFLAMMATORY BOWEL DISEASES

MAY 19-20 2023

**KATHOLISCHE AKADEMIE
BERLIN**

registration
is free!

ABSTRACT DEADLINE: 31 MARCH 2023

Vision2030-TRR241@charite.de

TOPICS

- **INTESTINAL INFLAMMATION – KEY PATHWAYS**
- **LUMINAL FACTORS INFLUENCING INTESTINAL INFLAMMATION AND BEYOND**
- **MEMORY AND ANTIGEN-SPECIFIC RESPONSE**
- **INTESTINAL INFLAMMATION: UNEXPECTED NETWORKS**
- **TACKLING IBD WITH SYSTEMS BIOLOGY**

CONFIRMED SPEAKERS

- Aline Azabdaftari (Oxford/UK)
- David Artis (New York, US)
- Matthieu Allez (Paris, FR)
- Ahmed Hegazy (Berlin, DE)
- Eduardo Villablanca (Stockholm, SE)
- Harry Sokol (Paris, FR)
- Petra Bacher (Kiel, DE)
- Mathieu Uzzan (Créteil, FR)
- Thomas Vogl (Vienna, AT)
- Andrew MacPherson (Bern, CH)
- Zlatko Trajanoski (Innsbruck, AT)
- Matthias Friedrich (Oxford, UK)
- Timon Adolph (Innsbruck, AT)
- Jody Rosenblatt (London, UK)
- Sebastian Zundler (Erlangen, DE)
- Noah Palm (New Haven, US)
- Caroline Bosch-Voskens (Erlangen, DE)
- Maria Rescigno (Milan, IT)

More information about the TRR 241: www.transregio241.de

SUPPORTED BY:

DFG Deutsche
Forschungsgemeinschaft
German Research Foundation

abbvie

Galápagos
Pioneering for patients

Takeda

janssen
PHARMACEUTICAL COMPANIES
OF Johnson & Johnson

Bristol Myers Squibb

Pfizer